Thrombosis Journal最新文献

{"title":"Optimal timing of anticoagulation therapy for venous thromboembolism prevention after intracranial hemorrhage.","authors":"Qian Ni, Qinghe Wang, Jialin Qi, Jing Cai, Tong Qiao, Baoyan Wang","doi":"10.1186/s12959-026-00836-x","DOIUrl":"10.1186/s12959-026-00836-x","url":null,"abstract":"<p><p>OBJECTIVE: This study aimed to explore the optimal timing of anticoagulation initiation for the prevention of VTE in patients with ICH. METHODS: This retrospective cohort study enrolled consecutive patients in Nanjing Drum Tower Hospital and The Medical Information Mart for Intensive Care IV database in the United States who were diagnosed with ICH. The restricted cubic spline was fitted to explore the dose-response relationship between anticoagulation initiation time and clinical outcomes. Based on the identified inflection point, patients were stratified into the ≤ 2 days group and the >2 days group according to the timing of anticoagulant initiation. The primary outcome was a composite outcome of VTE and intracranial rebleeding events. RESULTS: A total of 3,841 patients were divided into ≤ 2 days group (n = 2047) and >2 days group (n = 1794). HRs for ≤ 2 days group and >2 days group of composite outcome, VTE and intracranial rebleeding events were 1.20 (1.02–1.43), 2.01 (1.59–2.55) and 0.68 (0.53–0.87). For the subgroup analysis, significant interactions were observed between gender, race, etiology, location of ICH, and treatment group for the composite outcome (P<0.05). Compared to the all other races, a difference was observed in the relationship between anticoagulation initiation time and outcome events in Asians. CONCLUSIONS: Initiating anticoagulation within 2 days of ICH can balance bleeding and thrombosis risks, and should be administered to patients of all races to optimize outcomes. </p>","PeriodicalId":22982,"journal":{"name":"Thrombosis Journal","volume":" ","pages":""},"PeriodicalIF":2.7,"publicationDate":"2026-02-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12955006/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146100771","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pulmonary origin and risk assessment of cancer-associated thrombosis.","authors":"Huan Sun, Qiaoli Zhai, Beiwei Xin, Lingyu Zhong, Kourong Shi","doi":"10.1186/s12959-026-00835-y","DOIUrl":"10.1186/s12959-026-00835-y","url":null,"abstract":"<p><p>Cancer-associated thrombosis (CAT) is a serious complication frequently observed in patients with cancer; however, its exact mechanism is not yet fully understood. Recent research in 2025 suggests that the lungs play a significant role in providing prothrombotic factors. Both primary and metastatic lung tumors have the potential to induce a state of hypercoagulability through various pathways, such as the secretion of procoagulant molecules, such as tissue factor (TF), triggering local inflammatory responses, platelet activation, and alterations in the function of vascular endothelial cells. Furthermore, the unique network of blood vessels and haemodynamic conditions in the lungs may contribute to the formation of thrombosis. Understanding the specific mechanisms by which lung cancer can lead to thrombosis is crucial for the early detection and intervention of CAT. This review delves into the intricate relationship between the tumor microenvironment in the lungs and the development of thrombosis, exploring the underlying molecular pathways involved in this relationship. By examining the prevention and treatment strategies for CAT currently used in clinical practice, with a focus on lung cancer-induced thrombosis, this review aims to establish a solid foundation for clinical management of these conditions.</p>","PeriodicalId":22982,"journal":{"name":"Thrombosis Journal","volume":" ","pages":"22"},"PeriodicalIF":2.7,"publicationDate":"2026-02-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12895775/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146100741","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The interaction of fibrinolysis and the complement system in patients with acute pulmonary embolism, treated with ultrasound-assisted catheter-directed thrombolysis.","authors":"Dominik F Draxler, Christopher D Barrett, Justine Brodard, Elizabeth R Maginot, Konstantina Chalkou, Heidi Ho, Charithani B Keragala, Dik Heg, Johanna A Kremer Hovinga, Ernest E Moore, Robert L Medcalf, Anne Angelillo-Scherrer, Stefan Stortecky","doi":"10.1186/s12959-026-00830-3","DOIUrl":"10.1186/s12959-026-00830-3","url":null,"abstract":"<p><p>Ultrasound-assisted catheter-directed thrombolysis (USAT) with recombinant tissue-type plasminogen activator (rt-PA) is widely used as a reperfusion approach for acute pulmonary embolism (PE). The fibrinolytic effector protease plasmin is known to be a potent activator of the complement system. The aim of this study was to better characterize the extent of complement activation during USAT, and its relationship with the fibrinolytic system. In this single-center cohort study of USAT for PE, pulmonary-arterial hemodynamic measurements were performed, and plasma samples obtained from 35 patients before treatment start and at 6 h (during infusion of rt-PA). Hemostatic properties were evaluated with thromboelastometry and assessment of fibrinolytic markers. In addition, levels of the complement components C3a, C4a, C5a, soluble C5b-9 (sC5b-9), Ba, Bb, factor H and factor I at these time points were determined. Several complement components, including the anaphylatoxin C3a, showed a reduction during USAT. We found a positive correlation of the plasmin-antiplasmin complex (plap complex) with factor H, yet a negative correlation with both Ba and Bb, C5a and sC5b-9. The potent plasmin-inhibitor, α2-antiplasmin, displayed a positive correlation with Ba and Bb, factor I and factor H. In addition, the anaphylatoxin C5a negatively, and Ba positively predicted treatment responsiveness to USAT. In conclusion, in the setting of acute PE and reperfusion therapy with USAT, there appears to be a competing effect between plasmin-mediated complement activation and a reduction of the inflammatory trigger by resolution of obstruction and ischemia. Complement activation in PE is downregulated during USAT, an effect exceeding the complement-activating properties of plasmin.</p>","PeriodicalId":22982,"journal":{"name":"Thrombosis Journal","volume":"24 1","pages":"17"},"PeriodicalIF":2.2,"publicationDate":"2026-01-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12853686/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146086833","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Portal vein thrombosis as a clinical dilemma in Echis carinatus envenomation: a case report and review of the literature.","authors":"Mohammad Kazem Amirbeigy, Hassanali Vahedian-Ardakani, Amir Pasha Amel Shahbaz, AmirHossein Abotorabi Zarchi, Farzad Rafiei, Shahab Sheikhalishahi","doi":"10.1186/s12959-026-00827-y","DOIUrl":"10.1186/s12959-026-00827-y","url":null,"abstract":"<p><p>BACKGROUND: Snakebite envenoming is a major neglected tropical disease, particularly in rural regions of tropical and subtropical countries. Echis carinatus (saw-scaled viper; SSV), prevalent in the desert regions of Iran, is a medically significant species of the Viperidae family whose venom disrupts hemostasis through potent procoagulant activity. While venom-induced consumption coagulopathy (VICC) is well recognized as a hemorrhagic complication, thrombotic sequelae are rare and poorly documented. CASE PRESENTATION: We report the case of a 15-year-old male who presented to the emergency department shortly after a SSV bite to the ankle. Initial manifestations included local swelling, mild bleeding, and dizziness. He was promptly treated with intravenous polyvalent antivenom, tetanus toxoid vaccination, and supportive therapy. Baseline investigations revealed coagulopathy, which normalized with treatment; however, serial follow-up demonstrated progressive cytopenias. At approximately three months post-envenomation, the patient developed abdominal pain. Imaging revealed aneurysmal dilatation of the portal vein, intrahepatic portal vein thrombosis (PVT), vascular collaterals, and splenomegaly. Endoscopic evaluation confirmed secondary esophageal varices consistent with portal hypertension. The patient underwent multiple sessions of endoscopic band ligation and was managed with apixaban, propranolol, and proton pump inhibition. Despite therapy, persistent splenomegaly and thrombocytopenia were observed. Review of available laboratory data suggests that the thrombotic process began within the first month following envenomation; however, due to delayed referral and limited access to specialized care, diagnosis and treatment were initiated after the thrombus had already produced irreversible sequelae. CONCLUSIONS: This case demonstrates a rare but serious thrombotic complication of SSV envenomation, mediated by a rebound hypercoagulable phase following VICC, progressing to PVT, portal hypertension, splenomegaly, and esophageal varices. While acute management of snakebite focuses on antivenom and supportive measures, this report highlights the importance of long-term surveillance to detect delayed vascular complications. Furthermore, it underscores how diagnostic and therapeutic delays can allow thrombotic processes to evolve into chronic, irreversible outcomes. Clinicians in endemic regions should maintain vigilance for both hemorrhagic and thrombotic manifestations of Echis carinatus envenoming. </p>","PeriodicalId":22982,"journal":{"name":"Thrombosis Journal","volume":"24 1","pages":"15"},"PeriodicalIF":2.7,"publicationDate":"2026-01-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12853592/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146094172","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"An integrative analysis of genetic factors reveals dysregulation of cytokines, immune signaling, and T cell activity as the underlying immune mechanisms in autoimmune immune thrombocytopenia.","authors":"Pratyusha Patidar, Tulika Prakash","doi":"10.1186/s12959-026-00833-0","DOIUrl":"10.1186/s12959-026-00833-0","url":null,"abstract":"<p><p>BACKGROUND: Immune thrombocytopenia (ITP) is an autoimmune disorder characterized by immune-mediated platelet destruction, leading to an abnormally reduced platelet count. While numerous susceptibility genomic loci have been identified, the genetic mechanisms and pathways driving ITP remain poorly understood. This limits treatment options to broad immunosuppressants that increase patient vulnerability. OBJECTIVE: This study aims to uncover the functional and biological significance of ITP-associated genetic variations by integrating bioinformatics approaches. It seeks to identify functional SNPs, key immune pathways, and potential drug targets to enhance understanding of ITP pathogenesis and support the development of targeted therapies. METHODS: An integrative bioinformatics approach was employed to identify expression quantitative trait loci (eQTL) and pathogenic SNPs, reconstruct protein-protein interaction (PPI) networks, perform gene ontology analysis, and explore potential drug targets. RESULTS: The study identified 60 eQTL and 6 pathogenic SNPs associated with ITP, along with over 300 gene ontology processes. 14 hub genes in the PPI network were linked to key immune mechanisms, including T cell dysfunction (CD40, CTLA4, FOXP3, IL-10, IL-4, TBX21), cytokine dysregulation (IFNG, IL-6, IL-10, IL-4, TNF-α, TGFB1), JAK/STAT signaling (JAK2, STAT1, STAT3), and pattern-recognition (TLR4). TNF-α emerged as the top-ranked hub gene. Additionally, several platelet related genes (HPA2, MPL, PRKCA, PTPN11, and others) were implicated in the analysis. CONCLUSION: Functional SNPs and hub genes identified in this study serve as potential biomarkers for ITP diagnosis and prognosis. Cytokine pathways and T cell subsets were highlighted as central players in ITP pathogenesis. The drug-gene interaction analysis further suggests potential therapeutic avenues through drug repurposing, offering insights into novel treatment strategies. </p>","PeriodicalId":22982,"journal":{"name":"Thrombosis Journal","volume":" ","pages":"25"},"PeriodicalIF":2.7,"publicationDate":"2026-01-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12918271/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146067100","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy, safety, and influencing factors of AngioJet mechanical thrombectomy versus catheter-directed thrombolysis in the treatment of acute lower limb deep vein thrombosis.","authors":"Min Chen, Changyun Le, Hai Lin, Liang Wang","doi":"10.1186/s12959-025-00814-9","DOIUrl":"10.1186/s12959-025-00814-9","url":null,"abstract":"<p><p>OBJECTIVE: This study compared the efficacy and safety of AngioJet mechanical thrombectomy and catheter-directed thrombolysis (CDT) in acute lower limb deep vein thrombosis (DVT), while also assessing predictors of thrombus clearance, patient experience, and economic impact. METHODS: A retrospective single-center study included 76 patients with acute lower limb DVT treated between January 2017 and January 2022. Patients received either AngioJet (n = 34) or CDT (n = 42). Clinical data included demographics, thrombus characteristics, thrombolysis duration, urokinase dosage, hospital stay, complications, 12-month Villalta scores and satisfaction ratings. Statistical comparisons used chi-square and t-tests; logistic regression identified predictors of grade III thrombus clearance. RESULTS: AngioJet achieved a significantly higher grade III clearance rate than CDT (70.6% vs. 45.2%, P < 0.05), with shorter thrombolysis duration, lower urokinase use, and reduced hospital stay (all P < 0.05). Puncture site bleeding rates were similar, but hemoglobinuria occurred more frequently with AngioJet (P < 0.01) and resolved after symptomatic care. At 12 months, Villalta scores were comparable, though slightly lower in the AngioJet group, suggesting potential post-thrombotic syndrome prevention. Independent predictors of grade III clearance were AngioJet treatment and symptom onset ≤ 7 days. AngioJet patients reported greater satisfaction with shorter stays and improved recovery. CONCLUSION: AngioJet mechanical thrombectomy offers superior thrombus clearance, shorter treatment times, and better patient-reported outcomes compared with CDT in acute lower limb DVT. Benefits are greatest in early-stage disease or heavy thrombus burden, supporting its broader clinical application. </p>","PeriodicalId":22982,"journal":{"name":"Thrombosis Journal","volume":" ","pages":"24"},"PeriodicalIF":2.7,"publicationDate":"2026-01-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12903206/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146012390","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"4G/5G polymorphism and plasma levels of plasminogen activator inhibitor-1 in essential thrombocythemia patients with driver mutational status.","authors":"Xueya Zhang, Xizhe Guo","doi":"10.1186/s12959-026-00828-x","DOIUrl":"10.1186/s12959-026-00828-x","url":null,"abstract":"<p><p>Essential thrombocythemia (ET) is a kind of myeloproliferative neoplasms. Thrombosis is one of the common symptoms, however, the incidence of thrombosis in ET with JAK2, CALR, MPL gene mutations varies greatly, and the underlying mechanism is unclear. The clinical data of 155 consecutive patients with ET were analyzed retrospectively. The plasminogen activator inhibitor-1 (PAI-1) 4G/5G polymorphism and plasma levels were measured by sequencing reaction universal kit and enzyme linked immunosorbent assay (ELISA), respectively. The mutational status in ET was detected by polymerase chain reaction (PCR). Thrombotic events were detected by Color Doppler Ultrasound, Computer Tomography (CT), Magnetic Resonance Imaging (MRI), angiography and D-dimer. Among 155 patients with ET, 21.3% (33/155) had thrombotic events, including 54.5% (18/33) of ischemic stroke, 36.4% (12/33) of ischemic heart disease and 9.1% (3/33) of venous thrombosis. Compared to the healthy control population, there was no significant difference between the occurrence of thrombotic events and the patient’s age, gender, and blood cell counts, except for platelet counts. The incidence of thrombotic events in JAK2 V617F mutation positive ET patients was significantly higher than that in CALR mutation positive and JAK2 V617F mutation negative ET patients (P < 0.05). The gene 4G4G polymorphism and plasma levels of PAI-1 in JAK2 V617F mutated ET patients were significantly higher than that in CALR mutated ET patients, respectively (P < 0.05). In patients with JAK2 V617F mutation positive ET, the incidence of thrombosis in 4G4G gene group and plasma levels of PAI-1 group were significantly higher than that in non 4G4G group, respectively (P < 0.05). The 4G4G gene polymorphism and high plasma levels of PAI-1 have potential value in predicting the risk factors for thrombosis in JAK2 V617F mutation positive ET compare to CALR mutation positive subjects.</p>","PeriodicalId":22982,"journal":{"name":"Thrombosis Journal","volume":" ","pages":"21"},"PeriodicalIF":2.7,"publicationDate":"2026-01-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12896023/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145994575","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Thromboembolic events associated with antiangiogenic monoclonal antibodies: a disproportionality analysis from FDA adverse event reporting system (FAERS) database.","authors":"Hong Zhou, Yanzhao Su, Jianrong Song, Lan Zhen","doi":"10.1186/s12959-026-00829-w","DOIUrl":"10.1186/s12959-026-00829-w","url":null,"abstract":"<p><p>BACKGROUND: Antiangiogenic monoclonal antibodies are increasingly used for various cancers. Although studies have reported thromboembolic events (TEEs) in patients receiving antiangiogenic monoclonal antibodies (mAbs), a comprehensive analysis of various thromboembolic events and their correlation with clinical outcomes is lacking. OBJECTIVES: To evaluate potential signals and clinical outcomes of thromboembolic events associated with antiangiogenic monoclonal antibodies. DESIGN: An observational, retrospective, and pharmacovigilance study based on the FAERS database collected from the first quarter of 2004 to the third quarter of 2024 was conducted. METHODS: The reporting odds ratio (ROR) and the Bayesian Information Criterion (IC) with 95% confidence intervals (CIs) were employed to assess the disproportionate reporting of TEEs linked with antiangiogenic mAbs. A multivariable logistic regression model was implemented to evaluate the association between TEEs and mortality outcomes. RESULTS: A total of 3319 TEEs with antiangiogenic mAbs were identified including bevacizumab intravenously (3117 reports), ramucirumab (95 reports), and aflibercept intravenously (107 reports) from health professionals. All three antiangiogenic mAbs detected positive signals, including VTE, PE, ATE, and overall TEEs. Interestingly, no positive signals for myocardial Infarction were detected for all the three antiangiogenic mAbs, and no cerebral ATE was detected for aflibercept. Additionally, no signal was detected when comparing the antiangiogenic mAbs directly with one another. Multivariable logistic regression analysis revealed that fatal TEEs occurred more frequently compared to non-TEE outcomes. This association reached statistical significance in the subgroup of reports for bevacizumab in colorectal cancer. CONCLUSION: This post-marketing data revealed that antiangiogenic mAbs had similar risks of TEEs. However, the occurrence of TEEs was associated with a higher risk of mortality. Due to the inherent limitations of pharmacovigilance data, these findings represent signals that require validation in prospective studies to establish causality. </p>","PeriodicalId":22982,"journal":{"name":"Thrombosis Journal","volume":" ","pages":"20"},"PeriodicalIF":2.7,"publicationDate":"2026-01-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12895867/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145994588","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The unexpected clot: unilateral brachial artery occlusion unmasking antithrombin III deficiency; case report and therapeutic considerations.","authors":"Mohammad Ameen Ishqair, Amal A Abu Jheasha, Anas Ameen Ishqair, Aliaa Khalili, Raed M A Isayed, Urwa A M Zarari","doi":"10.1186/s12959-025-00825-6","DOIUrl":"10.1186/s12959-025-00825-6","url":null,"abstract":"<p><p>BACKGROUND: Antithrombin III (AT III) deficiency is a rare autosomal dominant thrombophilia that typically predisposes carriers to venous thromboembolism. Arterial thrombosis is uncommon but may occur in severe quantitative or qualitative defects, particularly when compounded by exogenous risk factors such as estrogen exposure. CASE PRESENTATION: We report a 47-year-old woman on combined oral contraceptives who presented with acute left upper-extremity ischemia due to complete brachial artery occlusion. Emergency embolectomy was performed, but early re-thrombosis occurred. Laboratory studies showed reduced levels of antithrombin III confirmed by immunoradiometric testing, otherwise unremarkable in terms of thrombophilia and autoimmune screening. Genetic studies showed homozygosity of MTHFR 677T and ACE D.D. genes, both of which were looked upon in the context of this case as coincidental. The patient’s response to heparin therapy remained suboptimal until fresh frozen plasma infusion temporarily corrected antithrombin deficiency. Patient’s condition stabilized with chronic anticoagulation therapy using apixaban. DISCUSSION: This particular case illustrates the diagnosis and treatment difficulties that may be encountered in arterial thrombosis in the context of hereditary antithrombin III deficiency. Cases complicated by resistance to heparin are difficult in terms of anticoagulant therapy in the period preceding procedures, although DOACs are effective in anticoagulation irrespective of antithrombin levels. The triggering role of estrogen in this condition must be recognized in family screening. CONCLUSION: Acute upper-extremity arterial thrombosis can unmask hereditary AT III deficiency, particularly in the setting of estrogen therapy. Early surgical therapy, adjustment of antithrombin levels, and the switches to DOACs are essential in keeping the limbs viable and preventing further occurrences. This particular case illustrates the need to put together the different aspects of biochemistry and medicine in rare cases of thrombophilia. </p>","PeriodicalId":22982,"journal":{"name":"Thrombosis Journal","volume":" ","pages":"9"},"PeriodicalIF":2.7,"publicationDate":"2026-01-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12805698/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145971265","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Popliteal vein aneurysm presenting in a patient with cerebral infarction and patent foramen ovale: a rare case with complex thrombotic events.","authors":"Changhuai He, Yating Huang, Yiqing Li, Ping Lv, Chuanqi Cai","doi":"10.1186/s12959-026-00826-z","DOIUrl":"10.1186/s12959-026-00826-z","url":null,"abstract":"<p><p>Popliteal vein aneurysm (PVA) is a rare yet potentially serious vascular lesion that can lead to various complications, including thrombosis and pulmonary embolism. This case study examines a 29-year-old female patient whose cerebral infarction may have resulted from a thrombus within the PVA that entered the cerebral vascular system via a patent foramen ovale (PFO). The PVA was cured by open surgery for this patient. By conducting a thorough analysis of this patient’s clinical course, this study underscores the complexity and severity associated with PVA. Although angiography is regarded as the gold standard for diagnosing PVA, pharmacologic therapy often proves ineffective in preventing the recurrence of deep vein thrombosis (DVT). Consequently, surgical intervention has emerged as the preferred treatment option. This paper discusses the treatment strategies for PVA, risk factors for recurrence of PVA in the context of a literature review, offer novel insights and unique perspectives regarding its diagnosis and treatment.</p>","PeriodicalId":22982,"journal":{"name":"Thrombosis Journal","volume":" ","pages":"19"},"PeriodicalIF":2.7,"publicationDate":"2026-01-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12888138/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145960357","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}